English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Children and teenagers with severe atopic dermatitis (AD) refractory to standard treatment often require systemic treatment with anti-inflammatory and immunosuppressive drugs. The temperature-controlled laminar airflow (TLA) (AirsonettTM) device is a non-pharmaceutical addon treatment option for patients with poorly controlled allergic asthma. The TLA delivers filtered, allergen-free, particle-free air to the patient’s breathing zone during the night (Fig. 1). It has been shown to improve quality of life (QoL) and reduce symptoms and exacerbations of asthma (1). Aeroallergens have been shown to elicit AD (2). However, specific allergen immunotherapy, reduction in house dust mites, and avoidance measures for treating AD have shown mixed outcomes (3). The effect of TLA use in patients with AD has not been sufficiently investigated. We report here a case of a teenager with severe AD refractory to intensive topical treatment and phototherapy, which responded to overnight use of a TLA during a 12-month period.

Clinical Experience of Overnight Use of a Temperature-controlled Airflow Device in a Teenager with Severe Atopic Dermatitis